UNITY Biotechnology’s Investor and Analyst Day to Highlight UBX1325 Program in Age-Related Diseases of the Eye
11 oct. 2022 08h00 HE
|
Unity Biotechnology, Inc.
- Presentations from UNITY’s leadership team and fireside chat with retina expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 from 8:00 a.m. to 9:30 a.m. ET - SOUTH SAN FRANCISCO,...
UNITY Biotechnology to Host Investor and Analyst Day to Discuss Clinical Development Program for UBX1325 in Age-Related Diseases of the Eye
06 oct. 2022 08h00 HE
|
Unity Biotechnology, Inc.
-Webinar to feature presentation from retinal expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 at 5:00 a.m. PT/8:00 a.m. ET- SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE...
UNITY Biotechnology Completes Enrollment in Phase 2 ENVISION Study of UBX1325 in Wet Age-related Macular Degeneration
19 sept. 2022 08h00 HE
|
Unity Biotechnology, Inc.
Enrollment of 51 patients exceeds target by ~10% due to high interest in the study 16-week data anticipated in Q1 2023 and 24-week data anticipated in Q2 2023 SOUTH SAN FRANCISCO, Calif., Sept. 19,...
UNITY Biotechnology to Participate in Upcoming Investor Conferences
31 août 2022 08h00 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging,...
UNITY Biotechnology Announces Pricing of Upsized Underwritten Public Offering
17 août 2022 23h04 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology Announces Proposed Public Offering of Common Stock
16 août 2022 16h01 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) (Nasdaq:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology, Inc. Reports Second Quarter 2022 Financial Results and Business Updates
12 août 2022 07h05 HE
|
Unity Biotechnology, Inc.
- Announced Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema; single injection in subjects led to statistically significant and clinically meaningful...
UNITY Biotechnology Announces Positive Data in Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
12 août 2022 07h00 HE
|
Unity Biotechnology, Inc.
A single injection of UBX1325 led to a progressive, statistically significant, and clinically meaningful improvement in mean Best Corrected Visual Acuity (BCVA) at 12- and 18-weeks compared to sham...
UNITY Biotechnology to Host Investor Call on 12- and 18-week Data from Phase 2 BEHOLD Study of UBX1325 in Patients with DME
11 août 2022 17h45 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (Nasdaq: UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging,...
UNITY Biotechnology to Present Clinical Data at the American Society of Retina Specialists (ASRS) 40th Annual Scientific Meeting
12 juil. 2022 16h00 HE
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...